{"retracted":false,"update":{"timestamp":1358467200000,"doi":"10.1007/s00280-012-2064-y","type":"correction"},"doi":"10.1007/s00280-012-1972-1","journal":"Cancer Chemotherapy and Pharmacology","publisher":"Springer Nature","title":"Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023"}
